Patient Identification

Target Patient Population (NYHA III-IV)

Previous myocardial infarction (90 days or more) with scar (ischemic)​

  • Anteroseptal, apical, and/or anterolateral region​
  • Discrete acontractile (akinetic and/or dyskinetic)​
  • Transmural (>50%)​
Viable Myocardium

Image Training Manual

Learn how to qualify your patients


BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA.

Our News

Contact Us

© 2023 BioVentrix. All Rights Reserved. Powered by MedTech Momentum
The Revivent TC™ trademark is a federally registered trademark owned by BioVentrix. Any unauthorized use is expressly prohibited.
Investigational Device. Limited to Investigational Use Only In The United States.